Cargando…
SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in SF3B1 are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms...
Autores principales: | López-Oreja, Irene, Gohr, André, Playa-Albinyana, Heribert, Giró, Ariadna, Arenas, Fabian, Higashi, Morihiro, Tripathi, Rupal, López-Guerra, Mònica, Irimia, Manuel, Aymerich, Marta, Valcárcel, Juan, Bonnal, Sophie, Colomer, Dolors |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415613/ https://www.ncbi.nlm.nih.gov/pubmed/37562845 http://dx.doi.org/10.26508/lsa.202301955 |
Ejemplares similares
-
Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets
por: López-Oreja, Irene, et al.
Publicado: (2021) -
Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
por: Gimenez, Neus, et al.
Publicado: (2020) -
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
por: Steensma, David P., et al.
Publicado: (2021) -
Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
por: Silkenstedt, Elisabeth, et al.
Publicado: (2019) -
Molecular basis of differential 3′ splice site sensitivity to anti-tumor drugs targeting U2 snRNP
por: Vigevani, Luisa, et al.
Publicado: (2017)